2200 Bridge Pkwy
Suite 102
Redwood City, CA 94065
United States
650 549 1400
https://www.jaspertherapeutics.com/
Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 45
Name | Title | Pay | Exercised | Year born |
---|---|---|---|---|
Mr. Ronald A. Martell | President, CEO & Director | 1.01M | N/A | 1962 |
Dr. Judith Anne Shizuru M.D., Ph.D. | Co-Founder & Director | 296.3k | N/A | 1957 |
Mr. Jeetinder Singh Mahal M.B.A. | Chief Operating Officer | 648.72k | N/A | 1973 |
Ms. Patricia Carlos | Senior Vice President of Regulatory Affairs & Quality | N/A | N/A | N/A |
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It focuses on the development and commercialization of therapeutic agents for diseases, such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndrome, and conditioning regimens for stem cell transplantation. In addition, it is also developing stem cell transplants for rare diseases such as sickle cell disease, fanconi anemia, chronic granulomatous diseases, and GATA2 MDS, and severe combined immunodeficiency. Jasper Therapeutics, Inc. is headquartered in Redwood City, California.
Jasper Therapeutics, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.